These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 28185291)

  • 21. Systemic sclerosis in adults. Part I: Clinical features and pathogenesis.
    Jerjen R; Nikpour M; Krieg T; Denton CP; Saracino AM
    J Am Acad Dermatol; 2022 Nov; 87(5):937-954. PubMed ID: 35131402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Systemic sclerosis--pathogenesis, clinical manifestations and treatment].
    Radić M; Kaliterna DM; Fabijanić D; Radić J
    Lijec Vjesn; 2010; 132(5-6):162-8. PubMed ID: 20677623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Autoantibodies Targeting G-Protein-Coupled Receptors: Pathogenetic, Clinical and Therapeutic Implications in Systemic Sclerosis.
    Binda M; Moccaldi B; Civieri G; Cuberli A; Doria A; Tona F; Zanatta E
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reliability and validity of the Italian version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in patients with systemic sclerosis.
    Gualtierotti R; Ingegnoli F; Two R; Meroni PL; Khanna D; Adorni G; Becciolini A; Ciavarella T; Marfia G; Murgo A; Scalone L; Ughi N; Zeni S;
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S55-60. PubMed ID: 26339890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis.
    Forbes A; Marie I
    Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii36-9. PubMed ID: 19487222
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Symptoms related to gastrointestinal tract involvement and low muscularity in systemic sclerosis.
    Rosato E; Gigante A; Pellicano C; Villa A; Iannazzo F; Alunni Fegatelli D; Muscaritoli M
    Clin Rheumatol; 2022 Jun; 41(6):1687-1696. PubMed ID: 35149929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacotherapy of systemic sclerosis.
    Postlethwaite AE; Harris LJ; Raza SH; Kodura S; Akhigbe T
    Expert Opin Pharmacother; 2010 Apr; 11(5):789-806. PubMed ID: 20210685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis.
    Raja J; Nihtyanova SI; Murray CD; Denton CP; Ong VH
    Rheumatology (Oxford); 2016 Jan; 55(1):115-9. PubMed ID: 26320139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-resolution manometry compared with the University of California, Los Angeles Scleroderma Clinical Trials Consortium GIT 2.0 in Systemic Sclerosis.
    Abozaid HSM; Imam HMK; Abdelaziz MM; El-Hammady DH; Fathi NA; Furst DE
    Semin Arthritis Rheum; 2017 Dec; 47(3):403-408. PubMed ID: 28624173
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and validation of French version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument.
    Bae S; Allanore Y; Coustet B; Maranian P; Khanna D
    Clin Exp Rheumatol; 2011; 29(2 Suppl 65):S15-21. PubMed ID: 21586213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Esophageal involvement in scleroderma: gastroesophageal reflux, the common problem.
    Ntoumazios SK; Voulgari PV; Potsis K; Koutis E; Tsifetaki N; Assimakopoulos DA
    Semin Arthritis Rheum; 2006 Dec; 36(3):173-81. PubMed ID: 17045629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autoantibodies to stratify systemic sclerosis patients into clinically actionable subsets.
    Mahler M; Hudson M; Bentow C; Roup F; Beretta L; Pilar Simeón C; Guillén-Del-Castillo A; Casas S; Fritzler MJ
    Autoimmun Rev; 2020 Aug; 19(8):102583. PubMed ID: 32553611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vascular hypothesis revisited: Role of stimulating antibodies against angiotensin and endothelin receptors in the pathogenesis of systemic sclerosis.
    Cabral-Marques O; Riemekasten G
    Autoimmun Rev; 2016 Jul; 15(7):690-4. PubMed ID: 26970493
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of agents for the treatment of systemic sclerosis.
    Herrick AL
    Expert Opin Investig Drugs; 2001 Jul; 10(7):1255-64. PubMed ID: 11772249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
    Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
    Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A Uuifying hypothesis for the pathogenesis of systemic sclerosis based on the deficiency of transcription factor Fli1 - the development of a new animal model of systemic sclerosis -].
    Asano Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(6):475-87. PubMed ID: 25748132
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe gastrointestinal involvement in systemic sclerosis.
    Plastiras SC; Tzivras M; Vlachoyiannopoulos PG
    Clin Rheumatol; 2007 Jun; 26(6):1025-6. PubMed ID: 16550300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gastrointestinal Manifestations of Systemic Sclerosis.
    McFarlane IM; Bhamra MS; Kreps A; Iqbal S; Al-Ani F; Saladini-Aponte C; Grant C; Singh S; Awwal K; Koci K; Saperstein Y; Arroyo-Mercado FM; Laskar DB; Atluri P
    Rheumatology (Sunnyvale); 2018; 8(1):. PubMed ID: 30057856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From mechanisms of action to therapeutic application: A review on current therapeutic approaches and future directions in systemic sclerosis.
    Del Papa N; Zaccara E
    Best Pract Res Clin Rheumatol; 2015 Dec; 29(6):756-69. PubMed ID: 27107511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protective role of interleukin-6 in systemic sclerosis gastrointestinal tract involvement: case report and review of the literature.
    Frech TM; Hudson M
    Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S179-81. PubMed ID: 26339896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.